A safety-first AI foundation for rare cancer care

Gena Health operates a specialised rare cancer care platform serving patients with orphan diseases and complex oncological conditions. Moterra delivered a Rapid AI Assessment for a conversational, evidence-based patient and clinician experience - where medical accuracy, safety and compliance were the non-negotiables.

Gena Health serves patients with rare cancers - a population facing significant barriers accessing specialised medical information, complex treatment protocols and clinical trials. Existing static information delivery falls short of what these patients and their care coordinators actually need: personalised, evidence-based, safe answers, available around the clock, with a clinician always in the loop.

An evidence-based view with patient safety as the non-negotiable starting point.

A Rapid AI Assessment scoped to Gena Health’s context, with safety treated as a design constraint rather than a review step.

Throughout the engagement, Gena Health had access to Moterra Business AI Suite as a working sandbox, used to prototype and validate the core use cases against representative clinical data.

Gena Health’s leadership got a safety-first AI plan - model choice grounded in medical accuracy and safety, a HIPAA-aligned RAG architecture, a phased path to production, and a governance model built on clinician oversight - the kind of foundation patients, oncologists and regulators expect for rare cancer care.

What problem did Gena Health need to solve?

Gena Health serves patients with rare cancers - a population facing significant barriers accessing specialised medical information, complex treatment protocols and clinical trials. Existing static information delivery falls short of what these patients and their care coordinators actually need: personalised, evidence-based, safe answers, available around the clock, with a clinician always in the loop.

What did Moterra deploy for Gena Health?

A Rapid AI Assessment scoped to Gena Health’s context, with safety treated as a design constraint rather than a review step.

What results did Gena Health see?

Gena Health’s leadership got a safety-first AI plan - model choice grounded in medical accuracy and safety, a HIPAA-aligned RAG architecture, a phased path to production, and a governance model built on clinician oversight - the kind of foundation patients, oncologists and regulators expect for rare cancer care.

Where does the deployment run?

Inside the client’s own cloud tenant, in the region they choose. The deployment is Private Claude Cowork by Moterra, with admin, MDM and governance handled by Moterra AI Bridge. Moterra builds in AWS and Azure, operates as a data processor under a DPA covering UK and EU GDPR, and the stack is ISO 27001 and ISO 42001 certified across the AWS and Anthropic layers.

How long does a deployment like this take?

Standard deployment is typically live within one to two weeks, covering environment and region setup, the identity path from your SSO, managed configuration through your MDM, and the connector allowlist.

Bring the hardest questions to the first call.

Thirty minutes, a live demo, and a quote for your environment.

Moterra is a private AI deployment company and a Select Services Partner in the Claude Partner Network. We help businesses deploy Claude inside their own AWS or Azure environment, connect it to the tools they already use, and keep it secure and governed, so everyday processes get faster.

Solutions

Company